IKNAライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:47):

Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs...

Stats
本日の出来高	50 775.00
平均出来高	414 077
時価総額	63.70M
EPS	$0 ( 2024-03-12 )
次の収益日	( $-0.400 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.810
ATR14	$0.00600 (0.45%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-01	Germa Caroline	Buy	579 100	Stock Option (Right to Buy)
2024-02-29	Germa Caroline	Buy	0
2024-02-01	Ecsedy Jeffrey	Buy	100 000	Stock Option (Right to Buy)
2024-02-01	Marango Jotin	Buy	181 000	Stock Option (Right to Buy)
2024-02-01	Manfredi Mark	Buy	320 000	Stock Option (Right to Buy)

INSIDER POWER
95.90
Last 94 transactions
Buy: 20 809 745 \| Sell: 873 348

ボリューム相関

長: -0.09 (neutral)

短: -0.75 (moderate negative)

Signal:(65.784) Neutral

Ikena Oncology, Inc. 相関

10 最も正の相関
RMRM	0.946
APOP	0.919
CMPO	0.909
XLRN	0.907
CVT	0.903
BRACU	0.902
NVCN	0.9
PAIC	0.896
WTMA	0.894
TRHC	0.889

10 最も負の相関
BOCH	-0.939
MMAC	-0.917
NETE	-0.902
NAKD	-0.893
HFWA	-0.892
SYBT	-0.882
VIEW	-0.879
GRIN	-0.878
RPRX	-0.878
AHPI	-0.878

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Ikena Oncology, Inc. 相関 - 通貨/商品

0.04
( neutral )

-0.16
( neutral )

0.00
( neutral )

0.49
( neutral )

Ikena Oncology, Inc. 財務諸表

Annual	2023
収益:	$9.16M
総利益:	$8.14M (88.86 %)
EPS:	$-1.630

FY	2023
収益:	$9.16M
総利益:	$8.14M (88.86 %)
EPS:	$-1.630

FY	2022
収益:	$15.62M
総利益:	$13.58M (86.98 %)
EPS:	$-1.840

FY	2021
収益:	$30.99M
総利益:	$0.00 (0.00 %)
EPS:	$-0.951

Financial Reports:

No articles found.

Ikena Oncology, Inc.

Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, an oral inhibitor of aryl hydrocarbon receptor; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.